A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT07215559
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Macupatide — DRUGAdministered SC
- Eloralintide — DRUGAdministered SC
- Macupatide Placebo — DRUGAdministered SC
- Eloralintide Placebo — DRUGAdministered SC
Study Details
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Key Dates
- Start date
- Oct 16, 2025
- Status verified
- Jun 2026
- Primary completion
- Mar 31, 2027
- Completion
- May 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Macupatide (Macupatide + Eloralintide Placebo)Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC
- Experimental: Eloralintide (Elorlintide + Macupatide Placebo)Participants will be administered eloralintide SC and macupatide placebo SC
- Experimental: Macupatide + EloralintideParticipants will be administered eloralintide SC and macupatide SC
- Placebo Comparator: Placebo (Macupatide Placebo + Elorlintide Placebo)Participants will be administered eloralintide placebo SC and macupatide placebo SC
Primary Outcome Measure
Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 32 ]
Central Contacts
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or317-615-4559
- Physicians interested in becoming principal investigators please contact
Locations (26)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC | Gilbert | Arizona | 85296 | 480-691-2213 Sunildat Maheshwari (PRINCIPAL_INVESTIGATOR) |
| Synexus Clinical Research US, Inc. | Phoenix | Arizona | 85020 | 602-200-3814 Jeffrey Zacher (PRINCIPAL_INVESTIGATOR) |
| Pima Heart | Tucson | Arizona | 85741 | 520329-4139 Paul Bejarano (PRINCIPAL_INVESTIGATOR) |
| Precision Clinical Research | Sunrise | Florida | 33351 | Jeffrey Schneider (PRINCIPAL_INVESTIGATOR) |
| SKY Clinical Research Network Group-Brown | Atlanta | Georgia | 30331 | 888-659-4363 Tamara Brown (PRINCIPAL_INVESTIGATOR) |
| Teak Research Consults | Lawrenceville | Georgia | 30043 | Kamar Alabi (PRINCIPAL_INVESTIGATOR) |
| AGILE Clinical Research Trials, LLC | Sandy Springs | Georgia | 30328 | Vasundhara Cheekati (PRINCIPAL_INVESTIGATOR) |
| Pivotal Research Solutions | Stonecrest | Georgia | 30038 | Rabahuddin Syed (PRINCIPAL_INVESTIGATOR) |
| Rophe Adult and Pediatric Medicine/SKYCRNG | Union City | Georgia | 30291 | 470-317-3604 Dwight Blake (PRINCIPAL_INVESTIGATOR) |
| Vector Clinical Trials | Las Vegas | Nevada | 89128 | 702-750-0000 Cornell Calinescu (PRINCIPAL_INVESTIGATOR) |
| Premier Research | Trenton | New Jersey | 08611 | 609-392-6666 Herbert Conaway (PRINCIPAL_INVESTIGATOR) |
| PriMED Clinical Research | Dayton | Ohio | 45429 | 937-534-4201 William Randall (PRINCIPAL_INVESTIGATOR) |
| Mercy Family Clinic | Dallas | Texas | 75208 | 281-944-3610 Ebere Israel Azubuike, MD (PRINCIPAL_INVESTIGATOR) |
| Velocity Clinical Research, Dallas | Dallas | Texas | 75230 | Dan Lender (PRINCIPAL_INVESTIGATOR) |
| Biopharma Informatic, LLC | Houston | Texas | 77043 | 281-944-3610 Agadadash Kuliev (PRINCIPAL_INVESTIGATOR) |
| PlanIt Research, PLLC | Houston | Texas | 77079 | 713-973-3415 Prashant Koshy (PRINCIPAL_INVESTIGATOR) |
| Research Physicians Network, LLC | Houston | Texas | 77089 | 281-944-3610 Jawad Sarwar, MD (PRINCIPAL_INVESTIGATOR) |
| Aavon Clinical Trials | Richmond | Texas | 77407 | 713-282-5600 Namrata Dass (PRINCIPAL_INVESTIGATOR) |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | 210-545-4900 Michelle Welch (PRINCIPAL_INVESTIGATOR) |
| Texas Valley Clinical Research | Weslaco | Texas | 78596 | 956-431-8090 Eduardo Luna (PRINCIPAL_INVESTIGATOR) |
| Kalo Clinical Research | West Valley City | Utah | 84120 | 801-363-7353 Cuper Martinez (PRINCIPAL_INVESTIGATOR) |
| Eastern Virginia Medical School (EVMS) Medical Group | Norfolk | Virginia | 23510 | 757-446-5291 Elias Siraj (PRINCIPAL_INVESTIGATOR) |
| Clinical Research Partners, LLC | Richmond | Virginia | 23226 | 804-477-3045 Robert Call (PRINCIPAL_INVESTIGATOR) |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | Jeena Vaid (PRINCIPAL_INVESTIGATOR) |
| Rainier Clinical Research Center | Renton | Washington | 98057 | 425-251-1720 Frances Broyles (PRINCIPAL_INVESTIGATOR) |
| Universal Research Group | Tacoma | Washington | 98405 | 253-882-1070 Sabrina Benjamin (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gilbert, AZ
By condition
By specialty
By research site
Related Studies
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
- Early Tracking of Childhood Health Determinants (ETCHED) StudyRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Modifying Diet to Improve Gut MicrobiomeNot Yet Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida